ATPC vs. RNLX, CMAX, VSEE, UPHL, NIVF, ACON, DMTK, BTTX, AVHIU, and AONC
Should you be buying Agape ATP stock or one of its competitors? The main competitors of Agape ATP include Renalytix (RNLX), CareMax (CMAX), Vsee Health (VSEE), UpHealth (UPHL), NewGenIvf Group (NIVF), Aclarion (ACON), DermTech (DMTK), Better Therapeutics (BTTX), Achari Ventures Holdings Corp. I (AVHIU), and American Oncology Network (AONC). These companies are all part of the "healthcare" industry.
Renalytix (NASDAQ:RNLX) and Agape ATP (NASDAQ:ATPC) are both small-cap computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, community ranking, media sentiment, valuation, profitability and analyst recommendations.
In the previous week, Agape ATP had 2 more articles in the media than Renalytix. MarketBeat recorded 4 mentions for Agape ATP and 2 mentions for Renalytix. Renalytix's average media sentiment score of 0.75 beat Agape ATP's score of 0.30 indicating that Agape ATP is being referred to more favorably in the news media.
Agape ATP has lower revenue, but higher earnings than Renalytix. Agape ATP is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.
Renalytix currently has a consensus target price of $3.00, suggesting a potential upside of 753.49%. Given Agape ATP's higher possible upside, equities analysts clearly believe Renalytix is more favorable than Agape ATP.
Renalytix received 9 more outperform votes than Agape ATP when rated by MarketBeat users.
9.9% of Renalytix shares are held by institutional investors. Comparatively, 0.0% of Agape ATP shares are held by institutional investors. 18.3% of Renalytix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Agape ATP has a net margin of -173.63% compared to Agape ATP's net margin of -1,687.80%. Renalytix's return on equity of -102.90% beat Agape ATP's return on equity.
Summary
Renalytix beats Agape ATP on 8 of the 15 factors compared between the two stocks.
Get Agape ATP News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATPC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agape ATP Competitors List
Related Companies and Tools
